Nis Glavind Kruse

Nis Glavind Kruse brings more than 20 years of experience in the biopharmaceutical and diagnostics industries, with a deep expertise in precision oncology and global market expansion. As Chief Commercial Officer, Nis leads Pixelgen’s global commercial strategy, with a focus on scaling the business and accelerating the adoption of its protein interactomics technology across international markets. Prior to joining Pixelgen, Nis served in key leadership roles at Merck (MSD) in the United States, most notably as Executive Director and Head of Precision Medicine for Keytruda®. In this capacity, he was instrumental in the commercial diagnostic strategy and Dx partner management for one of the world’s most significant immuno-oncology therapies. Following his time at Merck, Nis served as Chief Commercial Officer at SSI Diagnostica, where he led the global commercial organization through a period of substantial growth.
Nis’s career also includes leadership roles at Agilent Technologies, where he oversaw global commercialization for the companion diagnostics business. He has a proven track record in big pharma and diagnostics of building high-performing teams, navigating complex FDA approvals, and establishing successful co-commercialization models. Nis is dedicated to bridging the gap between innovative technology and clinical utility to improve patient outcomes worldwide.